Mogamulizumab in Combination with Nivolumab in a Phase I/II Study of Patients with Locally Advanced or Metastatic Solid Tumors.
David S HongOlivier RixeVi K ChiuPatrick M FordeTomislav DragovichYanyan LouAsha Nayak-KapoorRom S LeidnerJames N AtkinsAgron CollakuFloyd E FoxMargaret A MarshallAnthony J OlszanskiPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
Combination of mogamulizumab with nivolumab for treatment of patients with locally advanced or metastatic solid tumors did not result in enhanced efficacy. Tolerability of mogamulizumab 1 mg/kg plus nivolumab 240 mg was acceptable.